Trinity Biotech Form 6-K details new EpiCapture epigenetic collaboration

Rhea-AI Filing Summary

Trinity Biotech plc submitted a Form 6-K to report a corporate update related to its EpiCapture prostate cancer testing technology. The company states that on November 14, 2025 it issued a press release announcing a collaboration to advance epigenetic analysis for its EpiCapture prostate cancer test, and has attached that release as Exhibit 99.1. The filing also notes that this report is incorporated by reference into Trinity Biotech’s existing registration statements on Form S-8.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

TRINITY BIOTECH PLC

(Name of Registrant)

IDA Business Park

Bray, Co. Wicklow, Ireland

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).

EXPLANATORY NOTE

On November 14, 2025, the Company issued a press release announcing its Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test. A copy of the press release is filed herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit		Description
99.1		Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRINITY BIOTECH PLC
		Trinity Biotech plc
		(Registrant)
	By:	/s/ John Gillard
		John Gillard
		Chief Executive Officer

Date:  November 14, 2025

FAQ

What did Trinity Biotech plc (TRIB) announce in the November 2025 Form 6-K?

Trinity Biotech plc reported that it issued a press release on November 14, 2025 announcing a collaboration to advance epigenetic analysis for its EpiCapture prostate cancer test, and it furnished that release as Exhibit 99.1.

What is the focus of Trinity Biotech’s new collaboration mentioned in the Form 6-K?

The collaboration is focused on advancing epigenetic analysis related to Trinity Biotech’s EpiCapture prostate cancer test, indicating work on molecular-level analysis techniques for this diagnostic product.

When did Trinity Biotech issue the press release about the EpiCapture collaboration?

Trinity Biotech issued the press release on November 14, 2025, and this press release is referenced and filed as Exhibit 99.1 in the Form 6-K.

Which exhibit in the Form 6-K covers the EpiCapture collaboration announcement?

The collaboration announcement is contained in Exhibit 99.1, titled “Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test.”

How does this Form 6-K relate to Trinity Biotech’s existing registration statements?

The Form 6-K states that it is being incorporated by reference into Trinity Biotech’s existing Form S-8 registration statements with file numbers 333-182279, 333-195232 and 333-253070.

Who signed the Trinity Biotech Form 6-K regarding the EpiCapture collaboration?

The report was signed on behalf of Trinity Biotech plc by John Gillard, the company’s Chief Executive Officer, dated November 14, 2025.